INTERVENTION 1:	Intervention	0
Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin	Intervention	1
drug	CHEBI:23888	14-18
cyclophosphamide	CHEBI:4026	31-47
Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2	Intervention	2
cyclophosphamide	CHEBI:4026	20-36
+ Avastin 15 mg/kg	Intervention	3
Q 3 weeks X 4 cycles	Intervention	4
x	LABO:0000148	10-11
Bevacizumab/Avastin: IV 15mg/kg 21 days	Intervention	5
Cyclophosphamide: 500mg per meter squared, IV every 21 days	Intervention	6
cyclophosphamide	CHEBI:4026	0-16
meter	UO:0000008	28-33
Doxorubicin: 60 mg per meter squared, IV every 21 days	Intervention	7
doxorubicin	CHEBI:28748,BAO:0000639	0-11
meter	UO:0000008	23-28
Inclusion Criteria:	Eligibility	0
The diagnosis of breast cancer established by biopsy.	Eligibility	1
breast cancer	DOID:1612	17-30
Normal kidney function	Eligibility	2
kidney	UBERON:0002113	7-13
function	BAO:0003117,BFO:0000034	14-22
Normal LVEF evaluated by MUGA Scan	Eligibility	3
>18 years of age	Eligibility	4
age	PATO:0000011	13-16
Good performance status defined by ECOG scale of 0 or 1	Eligibility	5
Consent	Eligibility	6
Women of childbearing potential must have a negative pregnancy test.	Eligibility	7
Use of effective means of contraception in subjects of child-bearing potential while on treatment and for at least 3 months thereafter.	Eligibility	8
Peripheral Neuropathy: must be < grade 1	Eligibility	9
peripheral neuropathy	HP:0009830,DOID:870	0-21
Hematologic (minimal values)	Eligibility	10
Absolute neutrophil count >1,500/mm3	Eligibility	11
Hemoglobin >8.0 g/dl	Eligibility	12
hemoglobin	CHEBI:35143	0-10
Platelet count >100,000/mm3	Eligibility	13
platelet count	CMO:0000029	0-14
Hepatic	Eligibility	14
Total bilirubin <ULN	Eligibility	15
AST, ALT, Alkaline Phosphatase must be within range	Eligibility	16
phosphatase	GO:0016791,BAO:0000295	19-30
range	LABO:0000114	46-51
Exclusion Criteria:	Eligibility	17
Patients with locally advanced breast cancer with skin ulcerations	Eligibility	18
breast cancer	DOID:1612	31-44
Stage IV breast cancer	Eligibility	19
breast cancer	DOID:1612	9-22
Inflammatory breast cancer	Eligibility	20
breast cancer	DOID:1612	13-26
Allergy to any component of the treatment regimen	Eligibility	21
allergy	HP:0012393	0-7
Women who are breast feeding	Eligibility	22
breast	UBERON:0000310	14-20
Pregnancy or refusal to use effective contraception	Eligibility	23
Inability to comply with study and/or follow-up procedures.	Eligibility	24
Current, recent, or planned participation in a experimental drug study	Eligibility	25
drug	CHEBI:23888	60-64
Blood pressure of >150/100 mmHg. Essential hypertension well controlled with anti hypertensives is not an exclusion criterion.	Eligibility	26
blood	UBERON:0000178	0-5
essential hypertension	DOID:10825	33-55
unstable angina	Eligibility	27
New York Heart Association Grade II or greater congestive heart failure	Eligibility	28
heart	UBERON:0000948	9-14
heart	UBERON:0000948	58-63
congestive heart failure	HP:0001635,DOID:6000	47-71
history of myocardial infarction within 6 months	Eligibility	29
history	BFO:0000182	0-7
myocardial infarction	HP:0001658,DOID:5844	11-32
history of stroke within 6 months	Eligibility	30
history	BFO:0000182	0-7
stroke	HP:0001297,DOID:6713	11-17
Clinical significant peripheral vascular disease	Eligibility	31
peripheral vascular disease	DOID:341	21-48
Evidence of bleeding diathesis or coagulopathy	Eligibility	32
Presence of central nervous system or brain metastasis	Eligibility	33
central nervous system	UBERON:0001017	12-34
brain	UBERON:0000955	38-43
major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0	Eligibility	34
day	UO:0000033	81-84
day	UO:0000033	95-98
Minor surgical procedure such as fine needle aspirations or core biopsy within 7 days prior to day 0	Eligibility	35
day	UO:0000033	81-84
day	UO:0000033	95-98
Pregnant or lactating	Eligibility	36
Urine protein: creatinine ratio >1.0 at screening	Eligibility	37
urine	UBERON:0001088	0-5
protein	CHEBI:36080,BAO:0000175	6-13
creatinine	CHEBI:16737	15-25
ratio	UO:0000190	26-31
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0	Eligibility	38
history	BFO:0000182	0-7
abscess	HP:0025615	79-86
day	UO:0000033	112-115
Serious, non-healing wound, ulcer, or bone fracture	Eligibility	39
ulcer	OAE:0004372	28-33
bone fracture	HP:0020110	38-51
Outcome Measurement:	Results	0
Percentage of Participants With Pathological Complete Response.	Results	1
Pathological complete response was defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the resected breast.	Results	2
cancer	DOID:162	91-97
breast	UBERON:0000310	150-156
Time frame: Participants were assessed during surgery, an average of one hour	Results	3
time	PATO:0000165	0-4
surgery	OAE:0000067	46-53
hour	UO:0000032	73-77
Results 1:	Results	4
Arm/Group Title: Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin	Results	5
drug	CHEBI:23888	31-35
cyclophosphamide	CHEBI:4026	48-64
Arm/Group Description: Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2	Results	6
cyclophosphamide	CHEBI:4026	43-59
+ Avastin 15 mg/kg	Results	7
Q 3 weeks X 4 cycles	Results	8
x	LABO:0000148	10-11
Bevacizumab/Avastin: IV 15mg/kg 21 days	Results	9
Cyclophosphamide: 500mg per meter squared, IV every 21 days	Results	10
cyclophosphamide	CHEBI:4026	0-16
meter	UO:0000008	28-33
Doxorubicin: 60 mg per meter squared, IV every 21 days	Results	11
doxorubicin	CHEBI:28748,BAO:0000639	0-11
meter	UO:0000008	23-28
Overall Number of Participants Analyzed: 39	Results	12
Measure Type: Number	Results	13
Unit of Measure: percentage of evaluable patients  41        (27.7 to 55.4)	Results	14
Adverse Events 1:	Adverse Events	0
Total: 39/39 (100.00%)	Adverse Events	1
Febrile Neutropenia  1/39 (2.56%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Heart failure  1/39 (2.56%)	Adverse Events	3
heart	UBERON:0000948	0-5
Diarrhea  3/39 (7.69%)	Adverse Events	4
diarrhea	HP:0002014,DOID:13250	0-8
Nausea/vomiting  4/39 (10.26%)	Adverse Events	5
Mucositis  3/39 (7.69%)	Adverse Events	6
mucositis	DOID:0080178	0-9
Fatigue  4/39 (10.26%)	Adverse Events	7
fatigue	HP:0012378	0-7
infection  3/39 (7.69%)	Adverse Events	8
Urinary tract infection  2/39 (5.13%)	Adverse Events	9
urinary tract infection	DOID:0080784	0-23
Musculoskeletal pain  6/39 (15.38%)	Adverse Events	10
pain	HP:0012531	16-20
Syncope  1/39 (2.56%)	Adverse Events	11
syncope	HP:0001279	0-7
Insomnia  3/39 (7.69%)	Adverse Events	12
insomnia	HP:0100785	0-8
Anxiety  2/39 (5.13%)	Adverse Events	13
anxiety	HP:0000739,DOID:2030	0-7
